Leading global experts have combined guideline recommendations and new clinical data with practical, case-based formats that approximate clinical reality to improve patient outcomes in the management of heart failure. This series is focused on changing clinical behavior in the recognition and diagnoses of hyperkalemia and iron deficiency in heart failure, through the application of emerging science into everyday practice.
To return to the Global Heart Failure Academy, please click here.
This educational series is developed by Medtelligence. Supported by an unrestricted educational grant from CSL Vifor.
Overcoming Clinical Inertia in Hyperkalemia Management
Overcoming Clinical Inertia in Hyperkalemia Management
Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
Hyperkalemia in CKD and HFrEF…What Am I Missing?
Hyperkalemia in CKD and HFrEF…What Am I Missing?
Clinical Implications of the Evidence from IV Iron Trials in Heart Failure
Clinical Implications of the Evidence from IV Iron Trials in Heart Failure
2023 ESC Guideline Updates: Where Are We with Iron Deficiency?
2023 ESC Guideline Updates: Where Are We with Iron Deficiency?
A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
What You Should Know About Managing Your Patients with Both CKD and Hyperkalemia
What You Should Know About Managing Your Patients with Both CKD and Hyperkalemia
What Is the Totality of Evidence for IV Iron Treatment Outcomes in Patients with Heart Failure?
What Is the Totality of Evidence for IV Iron Treatment Outcomes in Patients with Heart Failure?
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
Late-breaking First Response on AFFIRM-AHF
Late-breaking First Response on AFFIRM-AHF
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
Mechanisms in Heart Failure: Why Iron Deficiency Matters
Mechanisms in Heart Failure: Why Iron Deficiency Matters
Balancing RAASi Therapy and Potassium: Understanding How it Works
Balancing RAASi Therapy and Potassium: Understanding How it Works